Cymbalta Under FDA Review for Chronic Pain

An FDA advisory committee will meet today to review whether the antidepressant Cymbalta should be used as a treatment for chronic pain, despite risks that include liver damage and skin disease. Drugmaker Eli Lilly is seeking an indication for use in treatment of chronic pain, including pain related to arthritis and chronic low back pain. In briefing documents posted on Tuesday, FDA reviewers said four studies found Cymbalta worked better than the placebo at easing pain, but they...Full Story
Commenting on this article is closed.